![Cancers | Free Full-Text | Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations Cancers | Free Full-Text | Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations](https://www.mdpi.com/cancers/cancers-13-02075/article_deploy/html/images/cancers-13-02075-g001.png)
Cancers | Free Full-Text | Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations
![Epidemiology and Determinants of Survival for Primary Intestinal Non-Hodgkin's Lymphoma – A Population Based Study | medRxiv Epidemiology and Determinants of Survival for Primary Intestinal Non-Hodgkin's Lymphoma – A Population Based Study | medRxiv](https://www.medrxiv.org/content/medrxiv/early/2022/07/18/2022.07.17.22277680/F4.large.jpg)
Epidemiology and Determinants of Survival for Primary Intestinal Non-Hodgkin's Lymphoma – A Population Based Study | medRxiv
![Cancers | Free Full-Text | Immunosuppressive Microenvironment and Efficacy of PD-1 Inhibitors in Relapsed/Refractory Classic Hodgkin Lymphoma: Checkpoint Molecules Landscape and Macrophage Populations Cancers | Free Full-Text | Immunosuppressive Microenvironment and Efficacy of PD-1 Inhibitors in Relapsed/Refractory Classic Hodgkin Lymphoma: Checkpoint Molecules Landscape and Macrophage Populations](https://www.mdpi.com/cancers/cancers-13-05676/article_deploy/html/images/cancers-13-05676-g001.png)
Cancers | Free Full-Text | Immunosuppressive Microenvironment and Efficacy of PD-1 Inhibitors in Relapsed/Refractory Classic Hodgkin Lymphoma: Checkpoint Molecules Landscape and Macrophage Populations
![Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades - Liu - 2020 - Cancer Medicine - Wiley Online Library Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades - Liu - 2020 - Cancer Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/031bdff7-5f7e-4aeb-8b88-aca6898623f2/cam43037-fig-0001-m.jpg)
Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades - Liu - 2020 - Cancer Medicine - Wiley Online Library
![Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers - ScienceDirect Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497121000926-grabsf1.jpg)
Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers - ScienceDirect
![Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience | Blood Cancer Journal Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience | Blood Cancer Journal](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41408-020-0299-0/MediaObjects/41408_2020_299_Fig1_HTML.png)
Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience | Blood Cancer Journal
![Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK's Haematological Malignancy Research Network | British Journal of Cancer Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK's Haematological Malignancy Research Network | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fbjc.2015.94/MediaObjects/41416_2015_Article_BFbjc201594_Fig1_HTML.jpg)
Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK's Haematological Malignancy Research Network | British Journal of Cancer
![Prognostic nomogram incorporating inflammatory cytokines for overall survival in patients with aggressive non-Hodgkin's lymphoma - eBioMedicine Prognostic nomogram incorporating inflammatory cytokines for overall survival in patients with aggressive non-Hodgkin's lymphoma - eBioMedicine](https://www.thelancet.com/cms/asset/d00e63fb-b227-48be-88c7-eb6b73a6e023/gr1.jpg)
Prognostic nomogram incorporating inflammatory cytokines for overall survival in patients with aggressive non-Hodgkin's lymphoma - eBioMedicine
![Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission | Journal of Clinical Oncology Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission | Journal of Clinical Oncology](https://ascopubs.org/cms/10.1200/JCO.2017.72.2157/asset/images/large/jco.2017.72.2157f4.jpeg)
Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission | Journal of Clinical Oncology
![Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study | JCO Global Oncology Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study | JCO Global Oncology](https://ascopubs.org/cms/10.1200/GO.21.00265/asset/images/large/go.21.00265f3.jpeg)
Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study | JCO Global Oncology
![Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups | Blood Cancer Journal Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups | Blood Cancer Journal](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41408-020-00340-z/MediaObjects/41408_2020_340_Fig2_HTML.png)
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups | Blood Cancer Journal
![Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma | Signal Transduction and Targeted Therapy Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma | Signal Transduction and Targeted Therapy](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41392-023-01600-7/MediaObjects/41392_2023_1600_Fig2_HTML.png)
Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma | Signal Transduction and Targeted Therapy
Progression-free survival (PFS) (A) and overall survival (OS) (B) in... | Download Scientific Diagram
![Frontiers | Survival Trends in Patients Under Age 65 Years With Mantle Cell Lymphoma, 1995–2016: A SEER-Based Analysis Frontiers | Survival Trends in Patients Under Age 65 Years With Mantle Cell Lymphoma, 1995–2016: A SEER-Based Analysis](https://www.frontiersin.org/files/MyHome%20Article%20Library/588314/588314_Thumb_400.jpg)